Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$2.65 USD
-0.16 (-5.69%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.71 +0.06 (2.26%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SONN 2.65 -0.16(-5.69%)
Will SONN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SONN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SONN
Sonnet BioTherapeutics (SONN) Expands Cancer Drug Study
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with ...
Sonnet BioTherapeutics expands clinical evaluation of SON-1010 dose escalation
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session